Publicaciones en colaboración con investigadores/as de Universitat de València (27)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Profile of plasma microRNAs as a potential biomarker of Wilson’s disease

    Journal of Gastroenterology, Vol. 59, Núm. 10, pp. 921-931

  3. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

    Archivos de Bronconeumologia, Vol. 60, Núm. 7, pp. 417-422

2023

  1. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  2. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  3. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

2022

  1. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)

    Annals of Oncology

  2. Longitudinal association of dietary acid load with kidney function decline in an older adult population with metabolic syndrome

    Frontiers in Nutrition, Vol. 9

  3. Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis

    Frontiers in Endocrinology, Vol. 13

  4. Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage

    Nature Communications, Vol. 13, Núm. 1

  5. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort

    Frontiers in Endocrinology, Vol. 13

2020

  1. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference

    Transplantation, Vol. 104, Núm. 6, pp. 1143-1149

2018

  1. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 29, pp. iv238-iv255

2017

  1. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

    Transplant Infectious Disease, Vol. 19, Núm. 6

  2. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

2016

  1. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

    Transplantation Reviews, Vol. 30, Núm. 3, pp. 119-143

2015

  1. Neuregulin-1β induces mature ventricular cardiac differentiation from induced pluripotent stem cells contributing to cardiac tissue repair

    Stem Cells and Development, Vol. 24, Núm. 4, pp. 484-496

  2. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

2013

  1. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer

    Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393

  2. Resumen de congreso: 20 años después del primer Simposium Internacional sobre el virus de la hepatitis C y otros virus relacionados

    Gastroenterologia y Hepatologia, Vol. 36, Núm. 10, pp. 641-646